CN-121991853-A - Enterococcus faecium, biological agent and application thereof in preventing and/or treating hyperuricemia

Abstract

The invention belongs to the technical field of biological bactericides, and particularly relates to enterococcus faecium Ef-13, a biological bactericides and application thereof in preventing and/or treating hyperuricemia. The enterococcus faecium Ef-13 or the biological agent can efficiently degrade uric acid in an animal body by feeding the animal, can reduce the level of uric acid by more than 45%, can reduce the liver and kidney metabolism burden caused by high uric acid, can improve the liver injury related index improvement rate in serum by more than 30%, has the effect of protecting kidneys and/or livers, can optimize the composition of intestinal microbiota, and can enhance the purine metabolism stability of the animal body.

Inventors

• ZHANG HONGYING
• ZHANG XUE
• FAN JUNYANG
• Mao Sai
• YANG MINGFAN
• JIN YUE

Assignees

• 河南农业大学
• 河南贾之湖生物科技有限公司

Dates

Publication Date

20260508

Application Date

20260227

Claims (10)

1. 1. Enterococcus faecium (Enterococcus faecium) Ef-13, wherein the preservation number of the enterococcus faecium Ef-13 is CGMCC No.37038.
2. 2. A biological agent comprising enterococcus faecium Ef-13 according to claim 1.
3. 3. The biological agent according to claim 2, characterized in that it comprises a fermentation broth and/or a bacterial suspension of enterococcus faecium Ef-13.
4. 4. The biological agent according to claim 1 or 2, wherein the effective viable count of enterococcus faecium Ef-13 in the biological agent is not less than 1 x 10 8 CFU/mL.
5. 5. The preparation method of the biological agent according to any one of claims 2-4, comprising the step of inoculating enterococcus faecium Ef-13 into a fermentation medium for shake culture to obtain the biological agent.
6. 6. The enterococcus faecium Ef-13 according to claim 1 or the biological agent according to any one of claims 2-4 or the biological agent prepared by the preparation method according to claim 5, and the application thereof in preparing medicines for preventing and/or treating hyperuricemia.
7. 7. The enterococcus faecium Ef-13 of claim 1 or the biological agent of any one of claims 2-4 or the biological agent prepared by the preparation method of claim 5, and the application thereof in preparing one or more of the following products: 1) Uric acid is reduced; 2) Protecting the liver and/or kidney; 3) Regulating intestinal flora; 4) And resisting pathogenic bacteria.
8. 8. The use according to claim 7, wherein the pathogenic bacteria comprise one or more of staphylococcus aureus (Staphylococcus aureus), escherichia coli (ESCHERICHIA COLI) and Salmonella (Salmonella).
9. 9. The medicine for preventing and/or treating hyperuricemia is characterized in that the effective component comprises enterococcus faecium Ef-13 according to claim 1 or the biological agent according to any one of claims 2-4 or the biological agent prepared by the preparation method according to claim 5.
10. 10. The use of enterococcus faecium Ef-13 according to claim 1 or the biological agent according to any one of claims 2 to 4 or the biological agent according to claim 5 or the medicament according to claim 9 for the preparation of animal feed additives and/or animal feeds.

Description

Enterococcus faecium, biological agent and application thereof in preventing and/or treating hyperuricemia Technical Field The invention belongs to the technical field of biological bactericides, and in particular relates to enterococcus faecium and a biological bactericides and application thereof in preventing and/or treating hyperuricemia. Background Because of the defect of urate oxidase genes, uric acid becomes a main final product of nitrogen metabolism of poultry, hyperuricemia (Hyperuricemia, HUA) is caused by the congenital physiological characteristic, and the poultry is cultivated intensively to form a metabolic disorder disease, and a core pathological mechanism is directly related to hyperuricemia or excretion dysfunction. The disease is widely spread to chickens, geese, turkeys and partial wild birds, and is particularly prominent in intensive farms, wherein 20-day-old young geese, old laying hens and broiler chickens are core susceptible groups, and the incidence rate can reach 20% -60%. Wherein, the high-calcium high-protein diet, the environmental stress of the poultry house, the nephrophilic virus infection and the like all induce or aggravate the illness state, so that the serum uric acid concentration is obviously increased, and along with glomerular injury, tubular fibrosis, inflammation activation and oxidative stress, obvious economic loss is caused for the poultry industry. In some researches known by the inventor, the intestinal tract is a core way of uric acid excretion, and the intestinal tract flora imbalance is closely related to the occurrence and development of HUA, and the efficient uric acid reducing scheme needs to have the synergistic functions of degrading intestinal uric acid, regulating flora balance, protecting liver and kidney and regulating purine metabolic genes. However, the existing control technology has obvious limitations, such as that although chemical drugs can temporarily regulate uric acid level, side effects are obvious, the intestinal tract-metabolism-liver-kidney multidimensional cooperative regulation capability is lacked, the problem of disease cause and organ damage is difficult to solve radically, the reduction of the protein content of feed can reduce purine intake, but the supply of necessary nutrition of poultry can be limited, and the feed only acts on the upstream ring node generated by uric acid, has no direct regulation effect on produced uric acid, and has limited actual uric acid reducing effect. It can be seen that the prior studies do not utilize the critical excretion pathway of the intestinal tract, and the inhibition of the uric acid efflux transporter (such as ABCG2 and GLUT 9) in the intestinal tract cannot be relieved by reducing the concentration of uric acid in the intestinal tract. Probiotics are active microorganisms beneficial to a host, play an important role in gastrointestinal health by regulating the balance of flora in the intestinal tract, and if a strain regulating the balance of flora in the intestinal tract can play roles in degrading uric acid in the intestinal tract, protecting liver and kidney, regulating purine metabolism and the like, the problem that the existing chemical medicines cannot synergistically regulate the functions of the intestinal tract, metabolism and liver and kidney can be solved. However, the strains having these functions in combination in the prior studies have yet to be further mined. Disclosure of Invention The invention aims to provide enterococcus faecium, a biological agent and application thereof in preventing and/or treating hyperuricemia, and enterococcus faecium Ef-13 can efficiently degrade uric acid in a body, simultaneously can relieve liver and kidney metabolism burden caused by the hyperuricemia, can optimize intestinal microorganism composition, and can enhance purine metabolism stability of the body, thereby achieving the effect of preventing and/or treating the hyperuricemia. The invention provides enterococcus faecium Ef-13, and the preservation number of the enterococcus faecium Ef-13 is CGMCC No.37038. The invention also provides a biological agent, which comprises the enterococcus faecium Ef-13 according to the technical scheme. Preferably, a fermentation broth and/or a bacterial suspension comprising enterococcus faecium Ef-13 is provided. Preferably, the effective viable count of enterococcus faecium Ef-13 in the biological agent is more than or equal to 1 multiplied by 10 8 CFU/mL. The invention also provides a preparation method of the biological agent, which comprises the following steps of inoculating enterococcus faecium Ef-13 into a fermentation medium for shake culture to obtain the biological agent. The invention also provides the enterococcus faecium Ef-13 according to the technical scheme or the biological agent according to the technical scheme or the application of the biological agent prepared by the preparation method according to the technical scheme in pre